Navigation Links
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Date:10/22/2008

http://www.transcept.com.

About Novacea

Novacea, Inc. is a biopharmaceutical company that had been focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including Asentar(TM), which had been in a Phase 3 clinical trial for androgen-independent prostate cancer, and AQ4N, a hypoxia-activated prodrug. There are currently no clinical trials planned or underway for either candidate.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept and Novacea disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing of closing the merger; the expected cash balance of the combined entity as of the closing; and the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, failure of Novacea stockholders to approve the merger; Novacea or Transcept inability to satisfy the conditions of the merger, or that the merger is otherwise delayed or ultimately not consummated; the rates of use of Transcept and Novacea cash and cash equivalents prior to the closing of the merger; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, obtaining regulatory approval, market acceptance and commercialization of Intermezzo
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Boston Scientific Corporation (NYSE: BSX ) ... $2 billion aggregate principal amount of its senior notes ... offering consists of $850 million of 4.50 percent notes ... due January 2020 and $300 million of 7.375 percent ... use the net proceeds for general corporate purposes, including ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/14/2009)... ThermoFab, a US-based thermoforming company, has completed the delivery of ... sheet metal to a plastic enclosure with a smaller footprint ... ... Shirley, MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based ... Flow Tester – helping Brookfield move from sheet metal to ...
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2
... 20 Sirion Therapeutics, Inc., a,privately held ... entered into an exclusive licensing agreement with,Bridge ... worldwide rights to develop and,market topical ophthalmic ... norketotifen., (Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO ), ...
... Altix XE Cluster and SGI InfiniteStorage Combination Delivers ... All Stages of Research, SUNNYVALE, Calif. and ... Genome Conference -- To create an optimal workflow,that ... Malaysia Genomics Institute (MGI) selected SGI (Nasdaq: ...
... According to,year-end statistics, LifeNet Health was able ... health to 265,967 patients in 2007., LifeNet ... transplant centers in its service area, to facilitate ... 303 lives could not have,been achieved without the ...
Other Biology Technology:Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases 2Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 2Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 3Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 4LifeNet Health Saves 303 Lives and Restores Health to 265,967 Patients in 2007 2
(Date:12/11/2009)... editor of the 4th edition of Springer,s classic reference ... given the Victor A. McKusick Leadership Award. The prize, ... of human genetics, was presented to him at the ... Genetics on 24 October 2009 in Honolulu, Hawaii. , ... at the University of Washington in Seattle. One of ...
(Date:12/11/2009)... ORFruit growers, profits have traditionally been limited ... where growing seasons can be short. Thanks ... varieties are being introduced that offer growers ... offseasonresulting in economic bonuses for both producers ... varieties of blackberry called "primocane-fruiting", which bear ...
(Date:12/11/2009)... smoking is a health risk but why do teens ... an evaluation for Faculty of 1000 Biology, Neil Grunberg ... abuse. , Grunberg describes the study, published by Natividad ... and suggests it "may have implications to help understand ... Nicotine increases the level of dopamine in the brain, ...
Breaking Biology News(10 mins):New management methods extend blackberry season 2Are manometric findings different between the patients with erosive and nonerosive disease 3F 62846 1Are manometric findings different between the patients with erosive and nonerosive disease 3F 62846 2Rodent smoke screen 11032 1Rodent smoke screen 11032 2Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 1Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 2Disability Firm Advocates for Valley 26apos 3Bs Needy Families 62842 3
... release is available in French . ... $100,000 grant from the Gates Foundation to help establish ... , "People are always asking why the pharmaceutical ... the poor, like parasitic infections," said Dr. Timothy Geary, ...
... touted by scientists and venture capitalists as "the next big ... creating artificial life in a laboratory and making the world,s ... cure for malariais expected on the market by 2010. ... that promises to conquer the globe,s energy problems seems just ...
... month that it is funding a new research effort ... and whether it is possible to build ... The $2 million grant is one of six NSF ... research. The Illinois team will tackle the engineering, social, ...
Other Biology News:Boost from McGill, Gates Foundation helps Africans control pharma research 2Synthetic Biology: Coming Up Fast! 2NSF funds research at Illinois on sustainable biofuels infrastructure 2NSF funds research at Illinois on sustainable biofuels infrastructure 3
... Reagent , 2 x 50 ml 10X TBST Wash ... 0.2 ml BL21 glycerol stock , 0.2 ml BLT5403 ... 1010 pfu T7Select Positive Control Lysate , 1010 ... HRP Conjugate , 2 ml T7Select S-protein , ...
...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: